Buy this Article for $7.95

Have a coupon or promotional code? Enter it here:

When you buy this you'll get access to the ePub version, a downloadable PDF, and the ability to print the full article.


  1. Aschenbrenner, Diane S. MS, APRN-BC


* The FDA is restricting access to rosiglitazone, used in the treatment of type 2 diabetes, until reassessment of its cardiovascular risk is completed.


* Patients shouldn't be started on rosiglitazone unless medically necessary; those already taking it have the option to continue.


* Everyone prescribing, taking, or dispensing the drug must be enrolled in the restricted-access program.